BioSpace News Archive

Axon Therapies, a private company focused on addressing a root cause of heart failure, announced 6-month results of the REBALANCE-HF randomized, blinded feasibility trial of the Splanchnic Ablation for Volume Management procedure for heart failure with preserved ejection fraction.

Bio-Thera Solutions, Ltd announced that its partner Biogen recently received notification from the United States Food and Drug Administration on the approval of TOFIDENCE intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA.

Bristol Myers Squibb and Mirati Therapeutics, Inc.® announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Mirati for $58.00 per share in cash, for a total equity value of $4.8 billion.

CANbridge Pharmaceuticals Inc., a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, announced the marketing approval of CAN108 by the Taiwan Food and Drug Administration.